Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
AssigneeTune Therapeutics, Inc.
InventorsJennifer KWON, Kendra CONGDON
Life of this patent
Estimating the term…
Loading patent…
AssigneeTune Therapeutics, Inc.
InventorsJennifer KWON, Kendra CONGDON
Estimating the term…
Provided in some aspects are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas/guide RNA (gRNA) systems for the transcriptional repression of genes to promote a cellular phenotype that leads to reduction of low-density lipoprotein (LDL). In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof that regulate LDL. In some embodiments, the systems are multiplexed systems that bind to or target a target site in at least two genes or regulatory elements thereof. Also provided herein are methods and uses related to the provided epigenetic-modifying DNA targeting systems in connection with treatments for cardiovascular disease and familial hypercholesterolemia.
A polynucleotide encoding an epigenetic-modifying DNA-targeting system, wherein the epigenetic-modifying DNA-targeting system is for repressing transcription of PCSK9 and comprises (a) a fusion protein comprising a dead Streptococcuspyogenes Clustered Regularly Interspaced Short Palindromic Repeats associated protein 9 (dSpCas9), a DNA-methyltransferase (DNMT) 3A/L domain, and a Kruppel associated box (KRAB) domain;
A polynucleotide encoding an epigenetic-modifying DNA-targeting system, wherein the epigenetic-modifying DNA-targeting system is for repressing transcription of PCSK9 and comprises (a) a fusion protein comprising an amino acid sequence that has at least 95% sequence identity to SEQ ID NO:278;
Dependencies are inferred from the claim text.